Skip to content

A randomized controlled trial for Aspirin or Rivaroxaban for venous thromboembolism prophylaxis after total joint arthroplasty

A randomized controlled trial for Aspirin or Rivaroxaban for venous thromboembolism prophylaxis after total joint arthroplasty

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800020289
Enrollment
Unknown
Registered
2018-12-22
Start date
2019-01-01
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoarthritis

Interventions

A:aspirin 100mg bid after operation
B:Rivaroxaban 10mg qd after operation

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. primary unilateral total knee or hip arthroplasty; 2. aged 20-80 years male and female; 3. aspirin user should stop using more than 1 week; 4. patient should agree to joint the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. patient who use aspirin for tertiary prevention or double antiplatelet therapy, including acute coronary syndrome in past 3 months, post-operation of PCI or cardiac valve replacement, and other high-risk patient; 2. patient with high risk of VTE, including previous VTE history, malignant tumor, hypercoagulable state, other known states that easily lead to thrombosis and undergoing anticoagulation; 3. patient with active ulcer that can not receive aspirin therapy or has aspirin intolerance; 4. patient with other severe disease in heart, brain, lung, kidney or blood; 5. patient with gastrointestinal hemorrhage history or OB test positive =3 times after admission; 6. patient with coagulation dysfunction, trend of hemorrhage or has active hemorrhage before operation; 7. patient with systematic artery stenosis or received stent implantation for such disease; 8. patient receiving total hip arthroplasty for femoral neck fracture; 9. patient with renal insufficiency.

Design outcomes

Primary

MeasureTime frame
prothrombin time;activated partial thromboplatin time;plasma thromboplastin antecedent;D-dimer;C-reaction protein;Ultrasound of deep vein of lower extremity;hemoglobin;hematocrit;platelet;type of blood transfusion;amount of blood transfusion;post-operation discomfort;circumference of both lower extremities;post-operation symptomatic VTE event;cardiovascular and cerebrovascular complication during medication;

Secondary

MeasureTime frame
blood pressure;Heart Rate;blood oxygen saturation;

Countries

China

Contacts

Public ContactXisheng Weng

Peking Union Medical College Hospital

xshweng@medmail.com.cn+86 13366200018

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 24, 2026